U.S. Virtual Clinical Trials Market Size, Share & Trends Analysis Report By Study Design (Interventional, Observational, Expanded Access), By Indication (Oncology, Cardiovascular), By Phase, By Region, And Segment Forecasts, 2023 - 2030

Table of Contents

Chapter 1. Methodology and Scope
                   1.1. Market Segmentation & Scope
                   1.2. Market Definitions
                   1.3. Information Procurement
                       1.3.1. Purchased Database
                       1.3.2. GVR’s Internal Database
                       1.3.3. Secondary Sources & Third-Party Perspectives
                       1.3.4. Primary Research
                       1.3.5. Details of Primary Research
                   1.4. Information Analysis
                       1.4.1. Data Analysis Models
                   1.5. Market Formulation & Data Visualization
                       1.5.1. Commodity Flow Analysis
                           1.5.1.1. Approach 1: Commodity flow approach
                           1.5.1.2. Approach 2: Country wise market estimation using bottom-up approach
                   1.6. Data Validation & Publishing
                   1.7. Global Market: CAGR Calculation
                   1.8. List of Secondary Sources
                   1.9. List of Primary Sources
Chapter 2. Executive Summary
                   2.1. Market Snapshot
                   2.2. Segmental Snapshot
                   2.3. Competitive Insights Snapshot
Chapter 3. Market Variables, Trends, and Scope
                   3.1. Market Lineage
                       3.1.1. Parent Market Analysis
                       3.1.2. Ancillary Market Analysis
                   3.2. U.S. Virtual Clinical Trials Market - Market Dynamics
                       3.2.1. Market Driver Analysis
                           3.2.1.1. The increasing healthcare digitization
                           3.2.1.2. The need for patient diversity clubbed with enhanced data collection in clinical trials
                           3.2.1.3. Adoption of telehealth
                           3.2.1.4. Alliances between biotechnology, pharmaceutical & clinical research organization
                       3.2.2. Market Restraint Analysis
                           3.2.2.1. Data security
                   3.3. Business Environmental Tools Analysis: U.S. Virtual Clinical Trials Market
                       3.3.1. Porter’s Five Forces Analysis
                       3.3.2. PESTLE Analysis
                   3.4. COVID-19 Impact Analysis
Chapter 4. U.S. Virtual Clinical Trials Market: Study Design Estimates & Trend Analysis
                   4.1. U.S. Virtual Clinical Trials Market, By Study Design: Key Takeaways
                   4.2. U.S. Virtual Clinical Trials Market: Study Design Movement & Market Share Analysis, 2022 & 2030
                   4.3. Interventional
                       4.3.1. Interventional Market Estimates And Forecasts, 2018 - 2030 (USD Billion)
                   4.4. Observational
                       4.4.1. Observational Market Estimates And Forecasts, 2018 - 2030 (USD Billion)
                   4.5. Expanded access
                       4.5.1. Expanded Access Market Estimates And Forecasts, 2018 - 2030 (USD Billion)
Chapter 5. U.S. Virtual Clinical Trials Market: Indication Estimates & Trend Analysis
                   5.1. U.S. Virtual Clinical Trials Market, By Indication: Key Takeaways
                   5.2. U.S. Virtual Clinical Trials Market: Indication Movement & Market Share Analysis, 2022 & 2030
                   5.3. Oncology
                       5.3.1. Oncology Market Estimates And Forecasts, 2018 - 2030 (USD Billion)
                   5.4. Cardiovascular
                       5.4.1. Cardiovascular Market Estimates And Forecasts, 2018 - 2030 (USD Billion)
                   5.5. Digestive Diseases
                       5.5.1. Digestive Diseases Market Estimates And Forecasts, 2018 - 2030 (USD Billion)
                   5.6. Musculoskeletal Diseases
                       5.6.1. Musculoskeletal Diseases Market Estimates And Forecasts, 2018 - 2030 (USD Billion)
                   5.7. Infectious Diseases
                       5.7.1. Infectious Diseases Market Estimates And Forecasts, 2018 - 2030 (USD Billion)
                   5.8. CNS
                       5.8.1. CNS Market Estimates And Forecasts, 2018 - 2030 (USD Billion)
                   5.9. Endocrinology & Metabolic Disease
                       5.9.1. Endocrinology & Metabolic Disease Market Estimates And Forecasts, 2018 - 2030 (USD Billion)
                   5.10. Others
                       5.10.1. Other Indications Market Estimates And Forecasts, 2018 - 2030 (USD Billion)
Chapter 6. U.S. Virtual Clinical Trials Market: Phase Estimates & Trend Analysis
                   6.1. U.S. Virtual Clinical Trials Market, By Phase: Key Takeaways
                   6.2. U.S. Virtual Clinical Trials Market: Phase Movement & Market Share Analysis, 2022 & 2030
                   6.3. Phase I
                       6.3.1. Phase I Market Estimates And Forecasts, 2018 - 2030 (USD Billion)
                   6.4. Phase II
                       6.4.1. Phase II Market Estimates And Forecasts, 2018 - 2030 (USD Billion)
                   6.5. Phase III
                       6.5.1. Phase III Market Estimates And Forecasts, 2018 - 2030 (USD Billion)
                   6.6. Phase IV
                       6.6.1. Phase IV Market Estimates And Forecasts, 2018 - 2030 (USD Billion)
Chapter 7. U.S. Virtual Clinical Trials Market: Regional Analysis
                   7.1. U.S. Virtual Clinical Trials Regional market share analysis, 2022 & 2030
                       7.1.1. Northeast
                           7.1.1.1. Northeast Market estimates and forecast, 2018 - 2030
                       7.1.2. Midwest
                           7.1.2.1. Midwest Market estimates and forecast, 2018 - 2030
                       7.1.3. South
                           7.1.3.1. South Market estimates and forecast, 2018 - 2030
                       7.1.4. West
                           7.1.4.1. West Market estimates and forecast, 2018 - 2030
Chapter 8. Competitive Landscape
                   8.1. Company Categorization
                   8.2. Strategy Mapping
                   8.3. Company Profiles/Listing
                       8.3.1. ICON, plc
                           8.3.1.1. Overview
                           8.3.1.2. Financial Performance
                           8.3.1.3. Service Benchmarking
                           8.3.1.4. Strategic Initiatives
                       8.3.2. Parexel International Corporation
                           8.3.2.1. Overview
                           8.3.2.2. Financial Performance
                           8.3.2.3. Service Benchmarking
                           8.3.2.4. Strategic Initiatives
                       8.3.3. IQVIA
                           8.3.3.1. Overview
                           8.3.3.2. Financial Performance
                           8.3.3.3. Service Benchmarking
                           8.3.3.4. Strategic Initiatives
                       8.3.4. Labcorp Drug Development
                           8.3.4.1. Overview
                           8.3.4.2. Financial Performance
                           8.3.4.3. Service Benchmarking
                           8.3.4.4. Strategic Initiatives
                       8.3.5. Medidata Solutions
                           8.3.5.1. Overview
                           8.3.5.2. Financial Performance
                           8.3.5.3. Service Benchmarking
                           8.3.5.4. Strategic Initiatives
                       8.3.6. Oracle
                           8.3.6.1. Overview
                           8.3.6.2. Financial Performance
                           8.3.6.3. Service Benchmarking
                           8.3.6.4. Strategic Initiatives
                       8.3.7. Signant Health
                           8.3.7.1. Overview
                           8.3.7.2. Financial Performance
                           8.3.7.3. Service Benchmarking
                           8.3.7.4. Strategic Initiatives
                       8.3.8. Medable, Inc.
                           8.3.8.1. Overview
                           8.3.8.2. Financial Performance
                           8.3.8.3. Service Benchmarking
                           8.3.8.4. Strategic Initiatives
                       8.3.9. Halo Health Systems
                           8.3.9.1. Overview
                           8.3.9.2. Financial Performance
                           8.3.9.3. Service Benchmarking
                           8.3.9.4. Strategic Initiatives
                       8.3.10. Science 37
                           8.3.10.1. Overview
                           8.3.10.2. Financial Performance
                           8.3.10.3. Service Benchmarking
                           8.3.10.4. Strategic Initiatives

List of Tables

Table 1 List of secondary sources
Table 2 List of abbreviations
Table 3 U.S. Virtual Clinical Trials market, by study design, 2018 - 2030 (USD Billion)
Table 4 U.S. Virtual Clinical Trials market, by indication, 2018 - 2030 (USD Billion)
Table 5 U.S. Virtual Clinical Trials market, by phase, 2018 - 2030 (USD Billion)
Table 6 U.S. Virtual Clinical Trials market, by region, 2018 - 2030 (USD Billion)

List of Figures

Fig. 1 U.S. virtual clinical trials market segmentation
Fig. 2 Market research process
Fig. 3 Data triangulation techniques
Fig. 4 Primary research pattern
Fig. 5 Market research approaches
Fig. 6 Value - chain - based sizing & forecasting
Fig. 7 QFD modeling for market share assessment
Fig. 8 Market formulation & validation
Fig. 9 Market snapshot
Fig. 10 Segment snapshot
Fig. 11 Competitive landscape snapshot
Fig. 12 Parent market outlook
Fig. 13 Related/ancillary market outlook
Fig. 14 U.S. Virtual Clinical Trials - Industry value chain analysis
Fig. 15 U.S. virtual clinical trials market driver analysis
Fig. 16 U.S. virtual clinical trials market restraint analysis
Fig. 17 U.S. virtual clinical trials market: Porter's Five Forces analysis
Fig. 18 U.S. virtual clinical trials market: PESTLE analysis
Fig. 19 U.S. virtual clinical trials market: Study design outlook and key takeaways
Fig. 20 U.S. virtual clinical trials market: Study design market share analysis, 2022 & 2030
Fig. 21 U.S. interventional study market, 2018 - 2030 (USD Billion)
Fig. 22 U.S. observational study market, 2018 - 2030 (USD Billion)
Fig. 23 U.S. expanded access study market, 2018 - 2030 (USD Billion)
Fig. 24 U.S. virtual clinical trials market: Indication outlook and key takeaways
Fig. 25 U.S. virtual clinical trials market: Indication market share analysis, 2022 & 2030
Fig. 26 U.S. oncology market, 2018 - 2030 (USD Billion)
Fig. 27 U.S. cardiovascular market, 2018 - 2030 (USD Billion)
Fig. 28 U.S. digestive diseases market, 2018 - 2030 (USD Billion)
Fig. 29 U.S. musculoskeletal diseases market, 2018 - 2030 (USD Billion)
Fig. 30 U.S. infectious diseases market, 2018 - 2030 (USD Billion)
Fig. 31 U.S. CNS market, 2018 - 2030 (USD Billion)
Fig. 32 U.S. endocrinology and metabolic diseases market, 2018 - 2030 (USD Billion)
Fig. 33 U.S. other indications market, 2018 - 2030 (USD Billion)
Fig. 34 U.S. virtual clinical trials market: Phase outlook and key takeaways
Fig. 35 U.S. virtual clinical trials market: Phase market share analysis, 2022 & 2030
Fig. 36 U.S. phase I virtual clinical trials market, 2018 - 2030 (USD Billion)
Fig. 37 U.S. phase II virtual clinical trials market, 2018 - 2030 (USD Billion)
Fig. 38 U.S. phase III virtual clinical trials market, 2018 - 2030 (USD Billion)
Fig. 39 U.S. phase IV virtual clinical trials market, 2018 - 2030 (USD Billion)
Fig. 40 Regional marketplace: Key takeaways
Fig. 41 Northeast U.S. virtual clinical trials market estimates and forecast, 2018 - 2030 (USD Billion)
Fig. 42 Midwest U.S. virtual clinical trials market estimates and forecast, 2018 - 2030 (USD Billion)
Fig. 43 South U.S. virtual clinical trials market estimates and forecast, 2018 - 2030 (USD Billion)
Fig. 44 West U.S. virtual clinical trials market estimates and forecast, 2018 - 2030 (USD Billion)
Fig. 45 Key company categorization
Fig. 46 Company market positioning
Fig. 47 Market participant categorization
Fig. 48 Strategy framework